LNCD(SH:600739) Ge Long Hui·2026-01-26 09:48Core Viewpoint - Liaoning Chengda (600739.SH) plans to establish a biopharmaceutical investment fund to enhance its competitiveness and seize market opportunities, with a total fund size not exceeding 100 million yuan, and an initial size of 50.2 million yuan [1][2] Group 1: Fund Structure and Contributions - The fund will be managed by Chengda Coastal as the general partner and will have contributions from various subsidiaries, with Liaoning Chengda contributing 10 million yuan (19.92% of the initial fund) and Chengda Biological contributing 40 million yuan (79.68% of the initial fund) [1] - Chengda Coastal and Shenzhen Chengda Biological will each contribute 1 million yuan, representing approximately 0.1992% of the initial fund [1] Group 2: Fund Focus and Future Plans - The fund will focus on the life and health sector during its investment period, with plans to raise the total contributions to 100 million yuan within three years [2] - Shenzhen Chengda Biological and Chengda Medical plan to increase their investment in Gene Qiming, with contributions of 40 million yuan and 10 million yuan respectively, to be transferred to the fund after its establishment [2]